Bioventus® Management to Present at Canaccord Genuity Growth Conference and Morgan Stanley Virtual Global Healthcare Conference
DURHAM, N.C., July 27, 2021 (GLOBE NEWSWIRE) — Senior management of Bioventus Inc. (Nasdaq: BVS)…
Month: July 2021
Clearside Biomedical to Report Second Quarter 2021 Financial Results and Provide Corporate Update on Tuesday, August 10, 2021
ALPHARETTA, Ga., July 27, 2021 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated…
SOPHiA GENETICS Announces Closing of $234 Million Initial Public Offering and $20 Million Private Placement
BOSTON and LAUSANNE, Switzerland, July 27, 2021 (GLOBE NEWSWIRE) — SOPHiA GENETICS SA (Nasdaq: SOPH),…
Zealand Pharma A/S – Final Transactions Under Share Repurchase Program
Company announcement – No. 47 / 2021 Zealand Pharma A/S – Final Transactions Under Share…
NexImmune to Announce Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
GAITHERSBURG, Md., July 27, 2021 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company…
XcelPlus International completes $1 million seed funding round, adds Ford Seeman to Board of Directors
Reno, NV, July 27, 2021 (GLOBE NEWSWIRE) — XcelPlus International Inc. (OTC Pink: XLPI) announced…
Bone Therapeutics agrees final settlement with the FSMA regarding clinical studies communication issues in 2016 and 2017
Bone Therapeutics to focus in future on the development of its MSC cell and gene…
Spectral Medical Inc. Closes $10 Million Offering of Units
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES…
Sunshine Biopharma Opens Twitter Account For Increased Shareholder Engagement
MONTREAL, July 27, 2021 (GLOBE NEWSWIRE) — Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical…
BioStem Technologies, Inc., Announces the Engagement of Biologics Consulting To Support FDA Strategies and Submissions.
Pompano Beach, Fl., July 27, 2021 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC PINK: BSEM)…
Medicenna Announces That Initiation of MDNA11 Phase 1/2 Study is on Track; Update to be Provided at the PropThink Digital Conference
– Phase 1/2 ABILITY Study is designed to evaluate MDNA11, a potentially best-in-class IL-2 Superkine,…
Allogene Therapeutics to Report Second Quarter Financial Results on August 4, 2021
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif.,…
The Odyssey Group International Sports Advisory Board Including Three Super Bowl MVPs will Appear on “Banfield” to Discuss Concussion Treatments
IRVINE, CA, July 27, 2021 (GLOBE NEWSWIRE) — Odyssey Group International, Inc. (OTCQB:ODYY) (the “Company”…
Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent
Potential for Affordable COVID-19 Immunization Coverage in Underserved African Countries Arrangement includes C1 COVID-19 vaccine…
Cidara Therapeutics to Present New Data for Rezafungin at the International Society for Human and Animal Mycology (ISHAM) Asia Congress
SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology…
Rhythm Pharmaceuticals to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
BOSTON, July 27, 2021 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed…
Nanox to Announce Second Quarter 2021 Financial and Operating Results on Tuesday, August 10, 2021
Management to host conference call and webcast at 8:30 AM ET on that day NEVE…
BetterLife Receives Approval to Conduct COVID-19 Randomized Placebo-Controlled Trial with Pontificia Universidad Católica de Chile
VANCOUVER, British Columbia, July 27, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
Radius Health Business Update
Added 5,000+ new TYMLOS patients in Q2, 2021, up 40+% vs. Q2, 2020 and 3%…
Kronos Bio Announces FDA Clearance of Investigational New Drug Application for Lanraplenib (LANRA) for Treatment of Patients with Acute Myeloid Leukemia (AML)
Company intends to develop LANRA as a once-daily chronic treatment for genetically-defined AML patients Two…